{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Each high-risk study will also be assigned a dedicated research compliance officer who will', 'monitor the trial. High-risk studies will be monitored by RCO personnel after the first patient', 'is enrolled and every three months thereafter during active enrollment. The RCO monitor will', 'review the study status and summarize enrollment, toxicities, SAEs, dose escalation, statistical', 'endpoints (e.g., stopping rules), deviations, etc. for the full DSMC membership at the regularly', 'scheduled meetings. Amendments which increase risk, change dosing, or impact study', 'objectives will be reviewed by the DSMC and approved by the PRMC and IRB. High-risk', 'trials will be formally reviewed by the DSMC after the first patient is enrolled and then', 'quarterly thereafter.', 'An initial audit of high-risk studies will be conducted by the RCO approximately one year', 'after enrollment begins and annually thereafter. Audits of high-risk studies may be conducted', 'more frequently as requested by the DSMC, IRB, PRMC, RCO management, or the PI.', 'Adverse Events and Serious Adverse Events', 'This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events)', 'Version 5.0 for AE and SAE reporting.', '16.2.1', 'Adverse Events (AEs)', 'An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical', 'condition occurring after starting the study drug even if the event is not considered to be related', 'to study drug. For the purposes of this study, the terms toxicity and adverse event are used', 'interchangeably. Medical conditions/diseases present before starting study drug are only', 'considered adverse events if they worsen after starting study drug. Abnormal laboratory values', 'or test results constitute adverse events only if they are considered clinically significant by the', 'treating investigator, or require therapy to treat.', 'Collection of adverse events will begin after the first dose of study drug and end at the Month', '18', 'visit or 30 days after the last dose of study drug if the patient is removed for progression', 'prior to this time point.', 'The safety profile for the drugs involved in this study have been characterized extensively in', 'previous clinical trials and standard clinical contexts. As such, safety data collection for this', 'study will be limited to > Grade 3 adverse events as defined by CTCAE v5.0.', 'Information about adverse events, whether volunteered by the subject, discovered by', 'investigator questioning, or detected through physical examination, laboratory test or other', \"means, will be abstracted from standard investigator clinic notes and recorded in the patient's\", 'study chart, at the interval noted in the study calendar.', 'Adverse events meeting the aforementioned recording criteria should be further evaluated,', 'either through abstraction of standard investigator clinic notes or through direct', 'correspondence with the treating investigator to determine:', '1. The severity grade based on CTCAE v5.0 (grade 1-5)', '2. Its relationship to the study drugs (definite, probable, possible, unlikely, not related)', '3. Its duration (start and end dates or if continuing at final exam)', 'Page 36 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '4. Action taken (no action taken; study drug dosage adjusted/temporarily interrupted;', 'study drug permanently discontinued due to this adverse event; concomitant', 'medication taken; non-drug therapy given; hospitalization/prolonged hospitalization)', '5. Whether it constitutes an SAE', 'All adverse events will be treated as medically appropriate.', 'All CTCAE v5.0 Grade 3 and above adverse events should be followed until its resolution or', 'the patient discontinues study, and assessment should be made at the interval noted in the study', 'calendar (or more frequently, if necessary) of any changes in severity, suspected relationship', 'to the study intervention, interventions employed to treat it, and outcome.', '16.2.2 Serious Adverse Event (SAE)', 'Information about all serious adverse events, as defined below, will be collected and recorded.', 'A serious adverse event is an undesirable sign, symptom or medical condition which:', 'Is fatal or life-threatening', 'Results in persistent or significant disability/incapacity', 'Is medically significant, i.e., defined as an event that jeopardizes the patient or may', 'require medical or surgical intervention to prevent one of the outcomes listed above', 'Causes congenital anomaly or birth defect', 'Requires inpatient hospitalization or prolongation of existing hospitalization, unless', 'hospitalization is for:', 'Routine treatment or monitoring of the studied indication, not associated with any', 'deterioration in condition (procedures such as central line placements, paracentesis,', 'pain control)', 'Elective or pre-planned treatment for a pre-existing condition that is unrelated to', 'the indication under study and has not worsened since the start of study drug', 'Treatment on an emergency outpatient basis for an event not fulfilling any of the', 'definitions of a SAE given above and not resulting in hospital admission', \"Social reasons and respite care in the absence of any deterioration in the patient's\", 'general condition', 'Collection of serious adverse events will begin at enrollment and end 30 after the last dose of', 'study treatment or until a new cancer treatment is initiated, whichever happens the soonest.', 'Any death from any cause while a patient is receiving treatment on this protocol or up to 30', 'days after the last dose of protocol treatment, or any death which occurs more than 30 days', 'after protocol treatment has ended but which is felt to be treatment related, must be reported.', 'Toxicities which fall within the definitions listed above must be reported as an SAE regardless', 'if they are felt to be treatment related or not.', 'Page 37 of 52']\n\n###\n\n", "completion": "END"}